Biocon has introduced Abraxane for breast cancer after failure of combination therapy.
Abraxane is a solvent-free chemotherapy treatment option developed using Abraxis. It is a paclitaxel protein-bound particles for injection suspension albumin-bound particles of approximately 130 nanometers is priced at $400 as against the current US price of $1,000 making it cheaper by 60 percent for scores of breast cancer patients.
Abraxane is now available as a single dose 100mg vial as a lyophilized powder to be reconstituted for intravenous administration and recommended to cases where breast cancer has relapsed after six months of adjuvant therapy.
As part of its major game plan to increase the portfolio of products in the bio-pharma space, Biocon has inked licensing pact with the US-based Abraxis BioScience. To begin with, Abraxane is being launched. Another product close on the heels for a possible India launch is Granulocyte colony-stimulating factor (G-CSF).
Discussions to launch more products are on. Under the terms of the agreement, Biocon can market Abraxane in India, Pakistan, Bangladesh, Sri Lanka, UAE, Saudi Arabia, Kuwait and select South Asian and Persian Gulf countries. The drug has several pending patent applications in India.
Since 2001, India has been a part of the global trial programme for Abraxane and the data was used by the company for approval of the drug from USFDA, stated Dr. Neil Desai, vice president, research and development, Abraxis BioScience.
The studies have proved that the drug has a 43 per cent success rate and 50 per cent positive response indication and as a first line of treatment the response was as high as 64 per cent, explained Dr. Desai.
Present market for the oncology drugs is estimated at Rs. 1500-1800 crore and this particular segment of paclitaxel drugs is valued around Rs. 80-100 crore. Biocon expects to garner Rs. 10 crore revenues in a year and is looking to make it a Rs. 100 crore product over the next three years, stated Kiran Mazumdar-Shaw, chairman and managing director Biocon.